Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides
Maneno muhimu
Kikemikali
Maelezo
Although OCTN2 is fairly well studied in its relationship with SCD, little is known about the carrier frequency of disease-causing alleles of OCTN2, or of more common functional polymorphisms in this gene. To address these issues, we screened for genetic variants in the OCTN2 coding region by direct sequencing of the exons and flanking intronic region of OCTN2 in a large sample (n = 276) of ethnically diverse subjects. In addition, we established lymphoblastoid cell lines from subjects homozygous for either allele of the previously identified promoter region variant, -207G>C. We found eight amino acid sequence variants of OCTN2, of which three (Phe17Leu, Leu144Phe, and Pro549Ser) were polymorphic in at least one ethnic group. When assayed for functional activity by expression in human embryonic kidney 293 cells, using as probes both the endogenous substrate (l-carnitine) and the organic cation tetraethylammonium, three variants showed functional differences from the reference OCTN2 (Phe17Leu, Tyr449Asp, Val481Phe; p < 0.05). Further studies of the Phe17Leu polymorphism showed a reduced V(max) for l-carnitine transport to approximately 50% of the reference OCTN2. Confocal microscopy studies using an OCTN2-GFP fusion protein showed that Phe17Leu had distinct subcellular localization from the reference OCTN2, with diffuse cytoplasmic retention of Phe17Leu, in contrast to reference OCTN2, which localized specifically to the plasma membrane. Lymphoblasts from subjects homozygous for the -207G allele showed increased l-carnitine transport compared with the -207C/C homozygotes (p < 0.05). This study suggests that although loss-of-function mutations in OCTN2 are likely to be rare, common variants of OCTN2 found in healthy populations may contribute to variation in the disposition of carnitine and some clinically used drugs.
Tarehe
Imethibitishwa Mwisho: | 08/31/2012 |
Iliyowasilishwa Kwanza: | 09/13/2005 |
Uandikishaji uliokadiriwa Uliwasilishwa: | 09/13/2005 |
Iliyotumwa Kwanza: | 09/15/2005 |
Sasisho la Mwisho Liliwasilishwa: | 09/10/2012 |
Sasisho la Mwisho Lilichapishwa: | 09/12/2012 |
Tarehe halisi ya kuanza kwa masomo: | 12/31/2004 |
Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 01/31/2008 |
Tarehe ya Kukamilisha Utafiti: | 01/31/2008 |
Hali au ugonjwa
Uingiliaji / matibabu
Other: Fasting
Awamu
Vikundi vya Arm
Mkono | Uingiliaji / matibabu |
---|---|
Fasting Other: Fasting blood and urine collection | Other: Fasting Not applicable no drugs dispensed |
Vigezo vya Kustahiki
Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
Jinsia Inastahiki Kujifunza | All |
Njia ya sampuli | Non-Probability Sample |
Hupokea Wajitolea wa Afya | Ndio |
Vigezo | Inclusion Criteria: - Previous participation in the "SOPHIE" study - Between the ages of 18 and 40 years old - Have a pre-selected genotype for OCTN1 and OCTN2 - Have been selected as healthy by medical history questionnaire and screening blood work (complete blood count [CBC], comprehensive metabolic panel). Exclusion Criteria: - Pregnant at the time of the study - Have a new history indicating they are no longer healthy - Taking a medication that could confound study results - Individuals with anemia (hemoglobin < 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL). - Do not consent to participate in the study. |